Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.
about
The role of magnetic resonance imaging in the diagnosis and management of prostate cancerUpdated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of referenceReview of Prostate Imaging Reporting and Data System version 2.Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.Prostate MRSI predicts outcome in radical prostatectomy patients.Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients.Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancerPerformance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancerRestriction spectrum imaging improves MRI-based prostate cancer detection.Role of MRI in prostate cancer detection.Functional and molecular imaging of localized and recurrent prostate cancer.Prostate-specific antigen-based prostate cancer screening: Past and future.Is contrast enhancement needed for diagnostic prostate MRI?The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.Are magnetic resonance imaging undetectable prostate tumours clinically significant? Results of histopathological analyses.Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancerMagnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination.Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL.The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience.Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy.Information of prostate biopsy positive core: does it affect MR detection of prostate cancer on using 3T-MRI?Detecting positive surgical margins: utilisation of light-reflectance spectroscopy on ex vivo prostate specimens.Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection.[MRI of the prostate].Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla.Genes involved in prostate cancer progression determine MRI visibility.Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents.Prostate cancer imagingComputed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection
P2860
Q26849794-7855CEC4-8D5D-489F-8A5B-AB299C6303E8Q30995961-33B31CEB-5F9A-47CB-9A6C-1BB92BD86F81Q31131775-4D3B22CE-F004-43B6-9159-9F4B62C921FAQ33783620-2BF5BD0B-5BC6-4512-9E06-F8B9D21735C9Q36879999-A595D6D5-74D2-4B65-9A79-B94E8056795EQ37009160-42E39B85-BCE9-41D0-A247-D2A0CA4BB441Q37626492-4F807C7F-5CE6-4434-BA8B-FCE0C156D8C8Q37709638-4F26B213-F079-4EAD-AE26-82375FC244DAQ37746751-3141A0A2-65BB-43ED-B762-98B7C90A8E4FQ38089710-E062A4CA-6BD6-41D9-923B-F27D43737C54Q38104639-CAD1FFA9-765C-4053-8992-9861E919915AQ38408501-2C42A90F-8E38-430C-B3D7-9A3C902DC556Q38671168-B5D88C79-F5CD-4EC5-8E64-751B186F8598Q38930394-B2305A6B-A652-49DE-B567-3595C0991955Q39024065-021C24CA-22C2-4965-96A7-010C9DF5FC33Q39211272-638F01D5-464B-4A7C-B9FB-92CAD104AE18Q40133335-F22948BF-24A9-4D95-8AB5-F8749B8469F0Q40206375-6742B566-25F6-4061-81A0-E7A69B74C95DQ40884788-D3BB9525-84CE-4685-A025-35DAD0282FDEQ41829663-5AF264B6-40AB-4906-B5A9-1A87065E5F10Q44248079-8E18F3A3-8B11-469B-8FA4-A8D9A217C1F9Q47796911-294DE8DC-6286-4280-9051-15808B23EC01Q50047697-5B07749D-A289-4152-9E20-A0823D233214Q50661010-AB241911-90BB-4228-9A37-8EB6CB36DC70Q52665654-CF3348E3-EE64-435B-842E-824AE1866279Q52878871-8A50159F-FCDF-4699-91FE-0AF98FE6C86DQ53064739-F9EF193C-1FB1-4882-89FE-A288528678E9Q55381843-A3436B41-FDC8-4425-95C3-04A0869DAC9AQ55709236-C3496091-C166-4E68-8B16-096C84F35701Q57780548-9EA535E4-1467-4447-8B24-D553E0036E1CQ57784098-0F681325-4627-496E-928A-4575F3F4FA59
P2860
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Performance characteristics of ...... e cancer: a prospective study.
@ast
Performance characteristics of ...... e cancer: a prospective study.
@en
type
label
Performance characteristics of ...... e cancer: a prospective study.
@ast
Performance characteristics of ...... e cancer: a prospective study.
@en
prefLabel
Performance characteristics of ...... e cancer: a prospective study.
@ast
Performance characteristics of ...... e cancer: a prospective study.
@en
P2093
P2860
P356
P1433
P1476
Performance characteristics of ...... e cancer: a prospective study.
@en
P2093
Amita Shukla-Dave
Chaya S Moskowitz
Debra A Goldman
Hebert Alberto Vargas
James A Eastham
Jingbo Zhang
Junting Zheng
Kent Kanao
Kristen L Zakian
Peter T Scardino
P2860
P304
P356
10.1148/RADIOL.12120041
P407
P577
2012-09-05T00:00:00Z